MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
Journal of Thoracic Oncology(2022)
摘要
Neoadjuvant nivolumab plus chemotherapy has recently received approval for early-stage non-small cell lung cancer. Prognostic factors capable to discriminate between patients at high- or low-risk of progression and death can be useful to tailor subsequent treatment.
更多查看译文
关键词
ctDNA levels, overall survival prediction, neoadjuvant CH-IO
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要